Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Dr. Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Mantosh Kumar Satapathy  | Taipei Medical University | Taiwan

Dr. Mantosh Kumar Satapathy, Ph.D., is a distinguished biomedical scientist, biotechnologist, pharmacologist, and tissue engineer based at Taipei Medical University, Taiwan, with extensive international experience in pharmacology, biomedical engineering, and nanobiotechnology. He earned his Ph.D. in Biomedical Materials and Tissue Engineering from Taipei Medical University, following an M.Tech. in Industrial Biotechnology and a Bachelor of Pharmacy, establishing a strong foundation in translational medical research. Dr. Satapathy has held postdoctoral and research fellow positions at leading institutions, leading projects on advanced nanodrug delivery systems, stem cell therapeutics, tissue engineering, and nanoformulation design, while supervising molecular biology laboratories and mentoring junior researchers. His research contributions include the development of stimuli-responsive nanocomposite hydrogels for orthopedic and skin tissue regeneration, engineering of nanocurcumin-based formulations for targeted therapies, and investigations into gene regulation and drug repurposing in cancer and skin pathologies. He has published extensively in high-impact peer-reviewed journals, contributed to international book chapters, co-invented a U.S. patent, and presented his work at global scientific conferences. Dr. Satapathy’s work has been recognized with multiple Outstanding Postdoctoral Researcher awards, and he actively serves as a peer reviewer, reflecting his leadership in the scientific community. He is a life member of professional organizations, has completed specialized research training in molecular diagnostics and biotechnology, and continues to advance interdisciplinary research that bridges fundamental science and clinical application, demonstrating exceptional impact in biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Banerjee, P., Satapathy, M., Mukhopahayay, A., & Das, P. (2014). Leaf extract mediated green synthesis of silver nanoparticles from widely available Indian plants: Synthesis, characterization, antimicrobial property and toxicity analysis. Bioresources and Bioprocessing, 1(1), 3.

2. Satapathy, M. K., Yen, T. L., Jan, J. S., Tang, R. D., Wang, J. Y., Taliyan, R., & Yang, C. H. (2021). Solid lipid nanoparticles (SLNs): An advanced drug delivery system targeting brain through BBB. Pharmaceutics, 13(8), 1183.

3. Satapathy, M. K., & Das, P. (2014). Optimization of crystal violet dye removal using novel soil-silver nanocomposite as nanoadsorbent using response surface methodology. Journal of Environmental Chemical Engineering, 2(1), 708–714.

4. Satapathy, M. K., Banerjee, P., & Das, P. (2015). Plant-mediated synthesis of silver-nanocomposite as novel effective azo dye adsorbent. Applied Nanoscience, 5(1), 1–9.

5. Satapathy, M. K., Nyambat, B., Chiang, C. W., Chen, C. H., Wong, P. C., Ho, P. H., … (2018). A gelatin hydrogel-containing nano-organic PEI–Ppy with a photothermal responsive effect for tissue engineering applications. Molecules, 23(6), 1256.

Ksenia Blinova | Pharmacology | Best Researcher Award

Dr. Ksenia Blinova | Pharmacology | Best Researcher Award

Associate Director at US Food and Drug Administration, United States

Dr. Ksenia Blinova, Ph.D., is the Associate Director for the Division of Applied Regulatory Science at the U.S. Food and Drug Administration, where she leads innovative research, regulatory reviews, and scientific consultations that advance translational science in support of public health. With a strong academic foundation in physics, mathematics, and cardiac electrophysiology, she has built a distinguished career focused on bridging fundamental science with regulatory applications. Since joining the FDA as a Commissioner’s Fellow, Dr. Blinova has held key leadership roles, including Deputy Director of the Division of Biomedical Physics, where she led multidisciplinary teams in developing over forty regulatory science tools that improved the evaluation of medical devices across fields such as cardiology, neurostimulation, diagnostics, and patient monitoring. Her career reflects a unique combination of scientific excellence, leadership, and commitment to advancing safe and effective medical products, making her an influential figure in the field of regulatory science.

Professional Profile 

Scopus Profile | ORCID Profile 

Education

Dr. Ksenia Blinova earned her undergraduate and doctoral degrees in Physics and Mathematics from Moscow State University, where she developed a strong foundation in quantitative sciences and analytical problem-solving. She further advanced her academic journey through a postdoctoral fellowship at the National Heart, Lung, and Blood Institute at the National Institutes of Health. Her research during this period centered on cardiac electrophysiology and metabolism, areas that deepened her expertise in biomedical applications of physical sciences. This educational trajectory not only equipped her with advanced technical knowledge but also gave her a unique interdisciplinary perspective that integrates rigorous physics and mathematical methodologies with life sciences and clinical research. Her educational background has been pivotal in shaping her ability to address complex regulatory and scientific challenges, contributing to her capacity for innovation and leadership in translational science and regulatory policy at the intersection of medicine, technology, and public health.

Experience

Dr. Blinova has built a distinguished career at the U.S. Food and Drug Administration, beginning as a Commissioner’s Fellow and progressing to influential leadership roles. As Deputy Director of the Division of Biomedical Physics in the Center for Devices and Radiological Health, she guided a multidisciplinary team in creating innovative regulatory science tools that addressed critical challenges in medical device safety and effectiveness. Her leadership was instrumental in developing methods and resources for fields such as cardiology, neurostimulation, ophthalmology, in-vivo diagnostics, and advanced patient monitoring. Currently serving as Associate Director for the Division of Applied Regulatory Science in the Office of Clinical Pharmacology, she oversees research, scientific consultations, and regulatory reviews that support the FDA’s translational science priorities. Through these roles, she has combined her technical expertise with strategic vision, ensuring that scientific advancements translate into practical regulatory applications that safeguard patient health and promote medical innovation.

Research Focus

Dr. Blinova’s research focuses on advancing translational and regulatory science to accelerate the safe and effective delivery of medical products to patients. Her early work in cardiac electrophysiology and metabolism provided insights into fundamental mechanisms of heart function, laying the groundwork for her later contributions in biomedical physics and device evaluation. At the FDA, she has led research efforts that integrate computational modeling, experimental studies, and regulatory tool development to address complex safety and efficacy challenges in medical devices and drug-device combinations. Her team has developed innovative approaches to evaluate technologies in cardiology, neurostimulation, electrical safety, diagnostics, and patient monitoring, ensuring that regulatory science keeps pace with rapid technological advances. By bridging basic science, applied research, and policy, her work exemplifies the role of regulatory science in translating innovation into tangible benefits for patients and healthcare systems, while maintaining a focus on safety, effectiveness, and public health impact.

Award and Honor

Throughout her career, Dr. Blinova has been recognized for her leadership, innovation, and contributions to regulatory science. Her accomplishments include guiding the development of over forty regulatory tools that have had a lasting impact on how medical devices are assessed for safety and effectiveness. These achievements reflect not only her scientific expertise but also her ability to collaborate across disciplines to solve pressing healthcare challenges. Her recognition within the FDA and broader scientific community underscores her role as a leader who consistently advances the field of translational science. Honors and awards in her career highlight her success in bridging science and regulation, her dedication to patient safety, and her influence in shaping modern approaches to medical product evaluation. These distinctions serve as a testament to her sustained contributions, her commitment to innovation, and her growing impact as a respected figure in regulatory and biomedical research.

Publication Top Notes

  • Title: Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential
    Authors: M. Iveth Garcia, Bhavya Bhardwaj, Keri Dame, Verena Charwat, Brian A. Siemons, Ishan Goswami, Omnia A. Ismaiel, Sabyasachy Mistry, Tromondae K. Feaster, Kevin E. Healy, et al.
    Year: 2025

  • Title: In Vitro Assay Development to Study Pulse Field Ablation Outcome Using Solanum Tuberosum
    Authors: Akshay Narkar, Abouzar Kaboudian, Yasaman Ardeshirpour, Maura Casciola, Tromondae Feaster, Ksenia Blinova
    Year: 2024
    Citations: 2

  • Title: Nonclinical evaluation of chronic cardiac contractility modulation on 3D human engineered cardiac tissues
    Authors: Tromondae K. Feaster, Jourdan K. Ewoldt, Anna Avila, Maura Casciola, Akshay Narkar, Christopher S. Chen, Ksenia Blinova
    Year: 2024

  • Title: Comprehensive Collection of Current Methods for Contractility and Electrophysiology Recordings in Human Cardiac Cells
    Authors: Ksenia Blinova, J. Pierson, A. Narkar
    Year: 2023

  • Title: Human in vitro assay for irreversible electroporation cardiac ablation
    Authors: Maura Casciola, Tromondae K. Feaster, M. J. Caiola, D. Keck, Ksenia Blinova
    Year: 2023

  • Title: Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models
    Authors: Tromondae K. Feaster, N. Feric, I. Pallotta, A. Narkar, M. Casciola, M. P. Graziano, R. Aschar-Sobbi, Ksenia Blinova
    Year: 2022

  • Title: Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2022

  • Title: Human in vitro neurocardiac coculture (iv NCC) assay development for evaluating cardiac contractility modulation
    Authors: Akshay Narkar, Tromondae K. Feaster, Maura Casciola, Ksenia Blinova
    Year: 2022

  • Title: Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells
    Authors: Maura Casciola, Devin Keck, Tromondae K. Feaster, Ksenia Blinova
    Year: 2022

  • Title: Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)
    Authors: Akshay Narkar, James M. Willard, Ksenia Blinova
    Year: 2022

  • Title: Cardiovascular medical devices: Regulatory science research overview in the office of science and engineering laboratories (OSEL) at the food and drug administration (FDA)
    Authors: K. Aycock, Ksenia Blinova, M. Casciola, B. Craven, M. Di Prima, G. D’Souza, N. Duraiswamy, M. Farahmand, P. Hariharan, L. Herbertson, et al.
    Year: 2021

  • Title: Acute effects of cardiac contractility modulation on human induced pluripotent stem cell–derived cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2021

Conclusion

Dr. Ksenia Blinova has demonstrated exceptional expertise and leadership in translational and regulatory science, particularly in the evaluation and development of cardiac therapies and medical devices. Her extensive body of research, including numerous high-impact publications on human in vitro cardiac models, contractility modulation, and electroporation assays, reflects a consistent focus on innovative approaches that bridge fundamental science with practical clinical and regulatory applications. She has led multidisciplinary teams to develop tools and methodologies that enhance patient safety, accelerate medical innovation, and provide reliable scientific evidence for regulatory decisions. Her work not only advances the understanding of cardiac electrophysiology and device performance but also sets new standards for predictive, nonclinical cardiac research. Overall, Dr. Blinova’s contributions exemplify the qualities of a pioneering researcher whose scientific rigor, leadership, and commitment to public health make her highly deserving of recognition in any Best Researcher Award.

Dr. Christian Seebauer | Pharmacology | Best Researcher Award

Dr. Christian Seebauer | Pharmacology | Best Researcher Award

Senior Consultant at Department of Oral and Maxillofacial Surgery / Plastic surgery, University Medicine Lübeck, Germany

Dr. med. Christian Seebauer, MD, DDS, is a distinguished clinician-scientist with dual qualifications in medicine and dentistry and board certifications in Oral and Maxillofacial Surgery and Oral Surgery. Currently a Senior Consultant at University Medical Center Lübeck, he has held several leadership roles in academic surgery. His research focuses on innovative therapies such as cold atmospheric plasma for cancer, wound healing, and oral diseases. He has authored impactful publications in high-ranking journals, with a strong emphasis on translational and interdisciplinary research. Awarded a summa cum laude for his medical doctorate, he is pursuing a second doctorate in dental medicine and a habilitation. Dr. Seebauer is actively involved in clinical trials, academic teaching, and scientific advising. His work reflects a commitment to advancing patient care through science, collaboration, and clinical excellence, making him a highly suitable candidate for prestigious research recognition such as the Best Researcher Award.

Professional Profile 

Google Scholar
Scopus Profile

Education

Dr. Christian Seebauer’s educational background reflects his exceptional commitment to interdisciplinary medical science. He earned his medical degree from Friedrich-Schiller-University Jena in 2006, graduating with high distinction and obtaining his medical license with a “very good” grade. Driven by an interest in craniofacial care, he pursued a second degree in dentistry at Ernst-Moritz-Arndt-University Greifswald, earning his dental license in 2015, again with top marks. He completed specialist training in Oral and Maxillofacial Surgery (2020) and Oral Surgery (2021), and is on track to receive an additional qualification in Plastic and Aesthetic Surgery by 2025. Academically, he achieved his Doctor of Medicine (summa cum laude) from Charité – Berlin in 2012, is completing a second doctorate in dental medicine, and is preparing his habilitation at University Medical Center Lübeck. His dual training uniquely equips him for complex surgical, academic, and translational roles in modern healthcare.

Professional Experience

Dr. Seebauer has accumulated extensive clinical and academic experience in leading German medical institutions. He began his residency in musculoskeletal surgery at Charité – Berlin (2007–2010), then transitioned into Oral and Maxillofacial Surgery at University Medical Centers in Jena and Greifswald. At Greifswald, he steadily advanced from resident to Specialist, then Senior Consultant, and eventually Managing Senior Consultant by 2023. In August 2024, he was appointed Senior Consultant at the University Medical Center Lübeck. Throughout his career, he has taken on multiple responsibilities beyond patient care, including roles in transfusion medicine, radiation safety, and medical coding. Dr. Seebauer is experienced in running clinical trials, mentoring young surgeons, and integrating advanced surgical techniques such as microvascular tissue transfer and plasma-based therapies. His professional trajectory demonstrates continuous growth in clinical leadership, academic excellence, and institutional trust, confirming his status as a respected authority in surgical and translational medicine.

Research Interest

Dr. Seebauer’s research centers on innovative, translational approaches to oral, mucosal, and dermal disease management, with a particular emphasis on cold atmospheric plasma. His work spans a range of high-impact medical themes, including wound healing, cancer therapy, precancerous lesions, chronic inflammation, and alternative cancer treatments. He has contributed significantly to both preclinical and clinical investigations, exploring how plasma technologies can improve outcomes in head and neck cancer, oral lichen planus, and leukoplakia. His recent studies include cohort analyses on the effects of anticoagulants on wound healing and the global impact of HPV vaccination on malignancy risks. He is actively involved in the planning of prospective, multicenter clinical trials and collaborates internationally via networks like TriNetX. His multidisciplinary approach combines surgery, oncology, immunology, and biomedical engineering, showcasing his ability to merge clinical insight with experimental innovation. These interests place him at the forefront of translational medical research in Europe.

Award and Honor

Dr. Christian Seebauer has earned several distinctions throughout his academic and clinical career. He was awarded his Doctor of Medicine degree summa cum laude, one of the highest academic honors in Germany, by the prestigious Charité – University Medical Center Berlin. His scientific work has been published in internationally renowned, peer-reviewed journals such as Radiology, Oral Diseases, and Pharmacological Research, some with impact factors exceeding 10. He has held trusted leadership roles, including Managing Senior Consultant, and serves as a Scientific Advisor to neoplas MED. His selection for these positions reflects institutional recognition of his scientific and clinical integrity. Although not explicitly listed, his rising trajectory in academic medicine and involvement in high-level research projects suggest a strong reputation within professional circles. His affiliations with organizations such as the National Center for Plasma Medicine and Rotary Club also highlight his commitment to service and excellence beyond his clinical duties.

Conclusion

Dr. Christian Seebauer exemplifies the ideal candidate for recognition as a Best Researcher. With dual qualifications in medicine and dentistry, a track record of clinical leadership, and a deep commitment to translational research, he bridges the gap between scientific discovery and patient care. His pioneering work in cold atmospheric plasma and its applications in oncology and regenerative medicine is both innovative and impactful, reflecting future-forward thinking in clinical science. His publication record, leadership roles, and collaborative involvement in global research initiatives further establish his credibility and influence in the medical community. Dr. Seebauer’s academic path—marked by excellence, versatility, and continual advancement—underscores his dedication to improving healthcare through research, education, and clinical innovation. As he continues his habilitation and leads new clinical trials, his contributions are poised to shape future standards in surgery and therapeutic technology. He is highly deserving of prestigious accolades such as the Best Researcher Award.

Publications Top Notes

  • Title: Clinical experience with cold plasma in the treatment of locally advanced head and neck cancer

    • Authors: HR Metelmann, C Seebauer, V Miller, A Fridman, G Bauer, DB Graves, …

    • Year: 2018

    • Citations: 353

  • Title: Head and neck cancer treatment and physical plasma

    • Authors: HR Metelmann, DS Nedrelow, C Seebauer, M Schuster, T von Woedtke, …

    • Year: 2015

    • Citations: 256

  • Title: Molecular mechanisms of the efficacy of cold atmospheric pressure plasma (CAP) in cancer treatment

    • Authors: ML Semmler, S Bekeschus, M Schäfer, T Bernhardt, T Fischer, K Witzke, …

    • Year: 2020

    • Citations: 216

  • Title: Comprehensive clinical plasma medicine: cold physical plasma for medical application

    • Authors: HR Metelmann, T Von Woedtke, KD Weltmann

    • Year: 2018

    • Citations: 162

  • Title: Visible tumor surface response to physical plasma and apoptotic cell kill in head and neck cancer

    • Authors: M Schuster, C Seebauer, R Rutkowski, A Hauschild, F Podmelle, …

    • Year: 2016

    • Citations: 152

  • Title: Cold atmospheric pressure plasma in wound healing and cancer treatment

    • Authors: L Boeckmann, M Schäfer, T Bernhardt, ML Semmler, O Jung, G Ojak, …

    • Year: 2020

    • Citations: 100

  • Title: Treating cancer with cold physical plasma: On the way to evidence‐based medicine

    • Authors: HR Metelmann, C Seebauer, R Rutkowski, M Schuster, S Bekeschus, …

    • Year: 2018

    • Citations: 65

  • Title: Hyperspectral imaging for in vivo monitoring of cold atmospheric plasma effects on microcirculation in treatment of head and neck cancer and wound healing

    • Authors: R Rutkowski, M Schuster, J Unger, C Seebauer, HR Metelmann, …

    • Year: 2017

    • Citations: 58

  • Title: Ankle laxity: stress investigation under MRI control

    • Authors: CJ Seebauer, HJ Bail, JC Rump, B Hamm, T Walter, UKM Teichgräber

    • Year: 2013

    • Citations: 55

  • Title: Side effects in cold plasma treatment of advanced oral cancer—Clinical data and biological interpretation

    • Authors: M Schuster, R Rutkowski, A Hauschild, RK Shojaei, T von Woedtke, …

    • Year: 2018

    • Citations: 48

  • Title: Physical plasma and leukocytes–immune or reactive?

    • Authors: S Bekeschus, C Seebauer, K Wende, A Schmidt

    • Year: 2018

    • Citations: 42

  • Title: Plasmamedizin

    • Authors: HR Metelmann, T von Woedtke, KD Weltmann

    • Year: 2016

    • Citations: 42

  • Title: Cold argon plasma as adjuvant tumour therapy on progressive head and neck cancer: A preclinical study

    • Authors: S Hasse, C Seebauer, K Wende, A Schmidt, HR Metelmann, …

    • Year: 2019

    • Citations: 41

  • Title: Third molars and periodontal damage of second molars in the general population

    • Authors: S Kindler, B Holtfreter, T Koppe, M Mksoud, C Lucas, C Seebauer, …

    • Year: 2018

    • Citations: 36

  • Title: Plasma-derived reactive species shape a differentiation profile in human monocytes

    • Authors: E Freund, J Moritz, M Stope, C Seebauer, A Schmidt, S Bekeschus

    • Year: 2019

    • Citations: 34